3SBio has filed for SFDA approval of a high-dose, 36,000 IU formulation of EPIAO for the treatment of anemia resulting from chemotherapy. Unlike 3SBio’s other formulations of EPO, this one would be exclusive to the company. A 36,000 IU injection would be administered once every week, a significant advantage over the three-times per week administration of the more common 10,000 IU injections. More details...

Stock Symbols: (NSDQ: SSRX)